SX29 is a non-competitive alpha-glucosidase inhibitor with oral activity, exhibiting an IC50 of 2.12 µM. It possesses hypoglycemic properties, oral administration of SX29 reduces blood glucose levels and enhances glucose tolerance in diabetic mice.
Target:
Glucosidase
* VAT and and shipping costs not included. Errors and price changes excepted
